Related Experiment Video
Updated: Jun 16, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
[Treatment of macroprolactinoma with cabergoline during pregnancy]
Gerardo Forsbach-Sánchez1, Héctor E Tamez-Pérez, Ricardo Hernández-Herrera
1Hospital de Ginecoobstetricia Dr. Ignacio Morones, Unidad Médica de Alta Especialidad 23, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León. gbforsbach@yahoo.com
Objective:
Management of macroprolactinomas in women who plan to get pregnant is controversial and when this happen there is a risk of pituitary enlargement, if this happens bromocriptine has a safe profile to be used during pregnancy, but if it is not tolerated cabergoline is a good alternative.
Clinical Cases:
We describe two patients with macroprolactinomas who intended to get pregnant. One of them had been previously treated surgically and the second one was treated with bromocriptine and got pregnant before the tomographic studies were checked. Both patients developed during pregnancy symptoms of macroprolactinoma enlargement and were initially treated with bromocriptine but this was not tolerated and were switched to cabergoline. Both pregnancies ended with a normal full term newborn.
Conclusion:
Pregnant women with symptoms of pituitary enlargement must be treated with bromocriptine, but if it is not tolerated cabergoline is a good choice.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Ovarian Cycle
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Mitral Valve Prolapse III: Nursing Management
